KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Edwards Lifesciences (EW) over the last 17 years, with Q3 2025 value amounting to $442.9 million.

  • Edwards Lifesciences' Other Non-Current Liabilities rose 2815.39% to $442.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $442.9 million, marking a year-over-year increase of 2815.39%. This contributed to the annual value of $426.0 million for FY2024, which is 2716.42% up from last year.
  • Per Edwards Lifesciences' latest filing, its Other Non-Current Liabilities stood at $442.9 million for Q3 2025, which was up 2815.39% from $421.6 million recorded in Q2 2025.
  • In the past 5 years, Edwards Lifesciences' Other Non-Current Liabilities registered a high of $442.9 million during Q3 2025, and its lowest value of $250.8 million during Q1 2021.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $303.7 million (2023), whereas its average is $322.7 million.
  • Over the last 5 years, Edwards Lifesciences' Other Non-Current Liabilities had its largest YoY gain of 3042.12% in 2021, and its largest YoY loss of 4307.85% in 2021.
  • Edwards Lifesciences' Other Non-Current Liabilities (Quarter) stood at $267.3 million in 2021, then increased by 0.07% to $267.5 million in 2022, then increased by 25.23% to $335.0 million in 2023, then rose by 27.16% to $426.0 million in 2024, then increased by 3.97% to $442.9 million in 2025.
  • Its last three reported values are $442.9 million in Q3 2025, $421.6 million for Q2 2025, and $402.6 million during Q1 2025.